School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Veracyte Inc VCYT

Healthcare · Biotechnology

$45.23last close 2026-10-09 · market cap $3.64B · delayed data

Trailing returns

1M+3.12%
3M-23.73%
6M+44.27%
1Y+29.49%
5Y+8.91%

Basis: Adjusted daily closes.

What it does

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer…

Open VCYT in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies